স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - levetiracetam - filmsko obložena tableta - levetiracetam 750 mg / 1 tableta - levetiracetam

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - levetiracetam - filmsko obložena tableta - levetiracetam 250 mg / 1 tableta - levetiracetam

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bioveta -

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hidroklorid - trombocitemija, esencialna - antineoplastična sredstva - anagrelide je primerna za zmanjšanje zvišane trombocitov šteje v grozi bistveno thrombocythaemia (et) bolnikov, ki so nestrpni do svoje trenutne terapije ali za katere je povišana trombocitov šteje se ne zmanjša na sprejemljivo raven z njihove trenutne terapije. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - predkroglomerna limfoma t-celična limfoblastna levkemija - antineoplastična sredstva - nelarabine je indiciran za zdravljenje bolnikov z t-celic acute lymphoblastic levkemijo (t-all) in t-celic lymphoblastic limfom (t-lbl), katerih bolezen ni odgovorila, ali je relapsed po zdravljenju z vsaj dvema kemoterapijo regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

hra pharma rare diseases - mitotane - adrenalne cortexove neoplazme - antineoplastična sredstva - simptomatsko zdravljenje napredovalega (neizrekljivega, metastatskega ali ponovnega) karcinoma nadledvičnih kortikotov. učinek lysodren na ne-funkcionalne nadledvične žleze, kortikalna karcinom ni vzpostavljena.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

pharma mar s.a. - trabektedin - ovarian neoplasms; sarcoma - antineoplastična sredstva - yondelis je indicirano za zdravljenje bolnikov z napredno mehkih tkiv sarkom, po odpovedi in antraciklini ifosfamid, ali ki se ne ujemajo s poslovanjem prejeli ti agenti. podatki o učinkovitosti temeljijo predvsem na liposarcoma in leiomyosarcoma bolnikov. yondelis v kombinaciji s pegylated liposomal doxorubicin (pld) je indiciran za zdravljenje bolnikov z relapsed platinum-občutljive rak na jajčnikih.